Stocks Pushing NASDAQ Up: CBMX, UNXL, GERN, ACUR, CLDX

CombiMatrix Corporation (NASDAQ:CBMX): The company stock is currently trading at $12.19, up 41.74 percent from its previous close. It had opened at $7.73 and has traded in the range of $7.24 and $14.11 in the current trading session.

CombiMatrix is currently in the bullish phase as it shot 67 percent up in its last trading session, before the trading was halted for the stock due to volatility. It ended the session at $8.60. The stock is showing the up move on the news of a couple of studies published in the New England Journal of Medicine. The studies are tangentially in favor or the company, however, the quantum of up move seems disproportional. CombiMatrix is a molecular diagnostic company and it offers various services such as genetic analysis. The company is based out of Irvine and its stock commands the beta of 0.33.

Uni-Pixel Inc. (NASDAQ:UNXL): The company reported its new agreement with a major PC marker company with regard to preferred pricing and capacity license agreement. The news sent the stock to new 52 weeks high in its previous trading session. The momentum still continues as Uni-Pixel is currently trading at $13.69, up 40.41 percent from its previous close of $9.75. The deal will help the company introduce new devices incorporating its UniBoss pro-cap sensor film. The stock is trading at the beta of -1.46. It has traded in the range of $4.54 and $13.89 in the past 52 weeks. However, the stock is trading above its 20 days moving average price of $13.24 and 50 days moving average price of $13.16. Uni-Pixel is based out of Texas and deals in performance engineered films. The company offers its services to electronics and computer companies. The stock has moved up on strong volumes as it has already traded 1.45 million shares in its current session, up from its usual trading volume of 94k shares.

Geron Corporation (NASDAQ:GERN): The stock is currently trading at $1.31, up 23.58 percent from its previous close of $1.06. Geron presented positive results for its Phase 2 study of Imetelstat. The company is currently studying the therapy’s effect on essential thrombocythemia. The stock is trading at the beta of 2.02. It has traded in the range of $0.91 and $2.99 in the past 52 weeks. Geron also reported the end of its technology licensing deal with Asia Biotech Corp. The company received $2.5 million for exiting the contract, which dealt with developing cosmetic treatments and dietary supplements. Geron is trading below its 20 days moving average price of $1.33 and 50 days moving average price of $1.35. The company is based out of Menlo Park in California and it was formed in 1990.

Acura Pharmaceuticals Inc. (NASDAQ:ACUR): The Illinois based company announced the launch of its next generation cold medicine. The company declared that the medicine may also be used to counter the effects of Meth and can be used as abuse-deterrent. Acura stock is currently trading at $1.88, up 31.60 percent from its previous close of $1.43. The stock had opened at $1.45 and has traded in the range of $1.45 and $1.964 in the current trading session. Its current trading volume stands at 515k shares, in comparison to its average daily volume of 86k shares. The stock commands the beta of 1.77. Acura uses its Impede and Aversion technologies for developing and marketing new therapies. The company was formed in 1935 and has agreement with King Pharmaceuticals Research and Development. Acura is currently trading above its 20 days moving average price of $1.87 and 50 days moving average price of $1.77.

Celldex Therapeutics Inc. (NASDAQ:CLDX): The stock is trading 22.28 percent up, at $6.75. The stock opened at $6.16 and has traded in the range of $6.15 and $7.14 in the current trading session. Its lowest price point in the past 52 weeks was at $2.53, while it touched its 52 weeks high of $7.14 today. Celldex reported positive results for the phase 2 study of its pipeline therapy CDX-011. The treatment is meant to treat aggressive and advanced breast cancer. The stock is currently trading above its 20 days moving average price of $6.69 and 50 days moving average price of $6.70. Celldex is based out of Massachusetts and it was formed in 1983.

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  Anton F Balint

• 

  Matthew Davison

• 

  Susan Marmor

• 

  Fiona Craig